News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
12 Apr 2022
byJairia Dela Cruz
Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.
12 Apr 2022

Which signs separate MIS-C from COVID-19, Kawasaki disease, toxic shock syndrome?
12 Apr 2022
byStephen Padilla
Children with multisystem inflammatory syndrome in children (MIS-C) show significantly higher prevalence of cardiac complications, elevated markers of inflammation and cardiac damage, thrombocytopenia, and lymphopenia than do those with COVID-19, Kawasaki disease (KD), and toxic shock syndrome (TSS), reports a study.
12 Apr 2022






